PORTOLA VALLEY, Calif., March 31 /PRNewswire/ -- Spectros Corporation (Portola Valley, CA) reported that 2007 year-over-year sales rose 36%, reflecting growing acceptance of molecular monitoring in the hospital for a broadening array of applications and clinical research areas. The Company's lead product, T-Stat(R), was the first device approved by the FDA as sensitive to ischemia, a condition in which critical organs receive insufficient oxygen. "We are pleased that hospitals are now recognizing the benefits of Ischemia Detection in their clinical practices," notes David Benaron, CEO. Red Herring recently predicted the market for such products in molecular detection, molecular imaging, and treatment guidance, will grow to over $12 billion annually. "We expect significant and continued growth in revenue for the next several years," noted David Benaron, CEO.
Spectros is currently the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat(R) 303 ischemia detection system. With introduction of probes that monitor in the cranial region, Spectros will compete directly with cerebral oximetry concerns such as Somanetics, CAS Medical, and others. Next generation products for the early diagnosis of breast cancer are entering Phase III trials. (Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor guarantees of future returns. Some applications described above are for investigation use only, and have not yet been reviewed or approved by the FDA.)
ABOUT THE COMPANY: Spectros Corporation is a venture-supported private corporation that makes advanced molecular sensing and imaging devices that shed light on life-threatening diseases, including ischemia and cancer. Spectros proprietary medical devices embed state-of-the-art biophotonic molecular technologies to enable real-time therapies that speed diagnosis, reduce complications, and lower costs. Spectros is a venture-supported private concern.
|SOURCE Spectros Corporation|
Copyright©2008 PR Newswire.
All rights reserved